In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m2 /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m2 ; cycles 4-8, 500 mg/m2 ). Responders were randomized to 12 8-week doses of R (375 mg/m2 ) or observation. As per intention-to-treat analysis, 82.4% (95% CI, 74.25-90.46%) of 85 patients achieved an overall response (OR), 16.5% a complete response (CR), 2.4% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4%, B 81.6%, and C 78.6%) and age categories (60-64 years, 92.3%; 65-69, 85.2%; 70-74, 75.0%; ≥75, 81.0%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patients
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients / R. Foà, I. Del Giudice, A. Cuneo, G. Del Poeta, S. Ciolli, F. Di Raimondo, F. Lauria, E. Cencini, G.M. Rigolin, A. Cortelezzi, F. Nobile, V. Callea, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, G. Specchia, F. Di Serio, L. Orsucci, A. Ambrosetti, M. Montillo, P.L. Zinzani, F. Ferrara, F. Morabito, M.A. Mura, S. Soriani, N. Peragine, S. Tavolaro, S. Bonina, M. Marinelli, M.S. De Propris, I. Della Starza, A. Piciocchi, A. Alietti, E.J. Runggaldier, E. Gamba, F.R. Mauro, S. Chiaretti, A. Guarini. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 89:5(2014 Jan), pp. 480-486. [Epub ahead of print] [10.1002/ajh.23668]
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients
A. Cortelezzi;
2014
Abstract
In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m2 /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m2 ; cycles 4-8, 500 mg/m2 ). Responders were randomized to 12 8-week doses of R (375 mg/m2 ) or observation. As per intention-to-treat analysis, 82.4% (95% CI, 74.25-90.46%) of 85 patients achieved an overall response (OR), 16.5% a complete response (CR), 2.4% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4%, B 81.6%, and C 78.6%) and age categories (60-64 years, 92.3%; 65-69, 85.2%; 70-74, 75.0%; ≥75, 81.0%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patientsFile | Dimensione | Formato | |
---|---|---|---|
ajh23668.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
501.56 kB
Formato
Adobe PDF
|
501.56 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.